Why NK Cells Are Becoming Central to the Next Wave of Cell Therapy
After a decade dominated by autologous CAR-T, the centre of gravity in cell therapy is quietly shifting. Natural killer (NK) cells — long studied as foundational innate effectors — are now positioned as one of the most credible platforms for the next generation of off-the-shelf, engineered, and combination immunotherapies.
Innate recognition without prior sensitization
NK cells recognize stressed, infected and transformed cells through a balance of activating receptors (NKG2D, NKp30, NKp44, NKp46, DNAM-1) and inhibitory receptors (KIRs, NKG2A) sensing “missing-self” signals (Vivier et al., Science, 2011; Myers & Miller, Nature Reviews Clinical Oncology, 2021). Unlike T cells, they do not require MHC-restricted antigen presentation, which collapses two long-standing barriers in cell therapy at once: the need for tumor-specific TCR engineering and the risk of graft-versus-host disease in the allogeneic setting (Liu et al., NEJM, 2020).
From proof-of-concept to multi-center programs
The 2020 New England Journal of Medicine report from MD Anderson — cord-blood-derived CD19 CAR-NK cells in CD19-positive lymphoid tumors — demonstrated objective responses without cytokine release syndrome, neurotoxicity or GvHD in the reported cohort (Liu et al., 2020). Since then, sponsor-led programs from Fate Therapeutics, Nkarta, Affimed, Sanofi (via Kiadis), Artiva, Wugen and academic consortia have advanced iPSC-derived, cord-blood-derived and peripheral-blood-derived NK platforms into multiple Phase 1/2 trials across hematologic and solid tumor indications (clinicaltrials.gov; reviewed in Berrien-Elliott et al., Blood, 2023).
Equally important is what has not happened: across the cumulative NK-cell experience, severe immune-mediated toxicities remain rare, supporting a fundamentally different safety profile from autologous CAR-T (Marofi et al., Stem Cell Research & Therapy, 2021).
A modular platform, not a single product
NK cells tolerate a wide range of engineering strategies: chimeric antigen receptors, membrane-bound IL-15 for persistence, CISH knockout to release cytokine signaling brakes (Daher et al., Blood, 2021), CD16 variants enabling antibody-dependent cellular cytotoxicity, and bispecific or trispecific NK-cell engagers (BiKEs/TriKEs) that redirect endogenous NK activity (Felices et al., Methods in Molecular Biology, 2016). iPSC-derived platforms further enable clonal, multi-edited master cell banks compatible with industrial-scale manufacturing (Goldenson et al., Frontiers in Immunology, 2022).
“The reason NK cells matter now is not that they replace CAR-T — it is that they let us redesign the entire delivery model of cell therapy. Off-the-shelf logistics, a more forgiving safety profile and modular engineering together open a path to cell therapies that can actually reach patients in middle-income health systems, not just academic centers in the United States or Europe.”
What still has to be solved
The momentum is real, but so are the open scientific questions. In vivo persistence of infused NK cells remains shorter than that of CAR-T, requiring strategies such as IL-15 armoring, repeat dosing or memory-like (cytokine-induced) NK programming (Romee et al., Science Translational Medicine, 2016). Trafficking and infiltration into solid tumors, immunosuppression by the tumor microenvironment, antigen heterogeneity, potency assay standardization and cryopreservation-induced functional loss are all active areas of translational research.
The field is also still negotiating its CMC vocabulary: what counts as a release-grade potency assay for an NK product is materially different from a T-cell product, and regulators are increasingly explicit about wanting orthogonal, mechanism-anchored evidence (FDA Guidance for Industry, Considerations for the Development of CAR T Cell Products, 2024; EMA reflection papers on advanced therapy medicinal products).
A platform, not a moment
The convergence of allogeneic biology, engineering tractability, an emerging safety record and a global access problem is what makes NK cells more than a scientific curiosity. The next wave of cell therapy is unlikely to be a single hero product. It will be a platform competition — and on the criteria that matter for scale, NK and CAR-NK are increasingly hard to ignore.
- Vivier E. et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
- Myers J.A., Miller J.S. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85–100.
- Liu E. et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545–553.
- Berrien-Elliott M.M. et al. Allogeneic natural killer cell therapy. Blood. 2023;141(8):856–868.
- Marofi F. et al. CAR-NK cell: a new paradigm in tumor immunotherapy. Stem Cell Res Ther. 2021;12:374.
- Daher M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624–636.
- Romee R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.
- Goldenson B.H. et al. iPSC-Derived Natural Killer Cell Therapies. Front Immunol. 2022;13:841107.
- Felices M. et al. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol. 2016;1441:333–346.
- U.S. FDA. Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products — Guidance for Industry. 2024.
Editorial disclaimer: This article is provided for scientific and educational purposes only. It does not constitute medical advice, investment guidance or claims of efficacy. BioNK programs are investigational and remain subject to CMC, nonclinical, clinical, regulatory and ethics validation. Citations refer to publicly available literature and regulatory documents; readers are encouraged to consult primary sources.